| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
Form 4: Hensley Mark Earl, Chief Operating Officer
Received 31,250 shares by exercise or conversion · Gave up 8,889 shares to cover exercise price or tax ($2.58K) |
| 09 Nov 2026 | DEFA14A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 | DEFA14A |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Q3 2026 net revenue of $35.3 million; ZYNRELEF® net revenue up 13.8% and APONVIE® net revenue up 49.3% compared to the third quarter of 2025 |
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +1 more
CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. |
| 03 Nov 2026 |
Form 4: Collard Craig A, Director
Received 50,021 shares by exercise or conversion · Gave up 12,181 shares to cover exercise price or tax ($3.41K) · Received 34,788 shares by exercise or conversion · 1 more |
| 03 Nov 2026 |
Form 4: Duarte Ira, EVP, Chief Financial Officer
Received 13,535 shares by exercise or conversion · Gave up 3,850 shares to cover exercise price or tax ($1.08K) · Received 11,695 shares by exercise or conversion · 1 more |
| 03 Nov 2026 |
Form 4: Forbes William P, EVP, Chief Development Officer
Received 11,770 shares by exercise or conversion · Gave up 3,349 shares to cover exercise price or tax ($938) · Received 11,695 shares by exercise or conversion · 1 more |
| 03 Nov 2026 |
Form 4: Hensley Mark Earl, Chief Operating Officer
Received 11,770 shares by exercise or conversion · Gave up 3,349 shares to cover exercise price or tax ($938) |
| 27 Oct 2026 | S-8 |
| 21 Oct 2026 |
Form 4: Duarte Ira, EVP, Chief Financial Officer
Received 3,874 shares by exercise or conversion · Gave up 1,102 shares to cover exercise price or tax ($397) |
| 21 Oct 2026 |
Form 4: Forbes William P, EVP, Chief Development Officer
Received 3,874 shares by exercise or conversion · Gave up 1,102 shares to cover exercise price or tax ($397) |
| 21 Oct 2026 |
Form 4: Collard Craig A, Director
Received 13,797 shares by exercise or conversion · Gave up 3,360 shares to cover exercise price or tax ($1.21K) |
| 29 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 23, 2026 (the “Effective Date”), Heron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a multi-product Development and License Agreement (the “License Agreement”) with Long Grove Pharmaceuticals, LLC... |
| 14 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders
This Amendment No. 1 to Tax Benefit Preservation Plan (this “Amendment”) is dated as of August 13, 2026 (the “Effective Date”), and amends that certain Tax Benefit Preservation Plan, dated as of August 14, 2025 (the “Plan”), by and betwe... |
| 10 Aug 2026 |
Form 4: Hensley Mark Earl, Chief Operating Officer
Received 31,250 shares by exercise or conversion · Gave up 8,888 shares to cover exercise price or tax ($4.44K) |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF® net revenue grew 35% and APONVIE® net revenue grew 74% year-over-year |
| 03 Aug 2026 |
Form 4: Hensley Mark Earl, Chief Operating Officer
Received 11,769 shares by exercise or conversion |
Loading...